High-dose medroxyprogesterone in disseminated breast cancer. Correlation between bioavailability and clinical response.
Clinical response to high-dose medroxyprogesterone (MPA), administered following three different routes of administration (i.m., p.o. + i.m., p.o.) and monitoring drug plasma levels, was evaluated in pretreated advanced breast cancer patients. Fifty-eight of 68 eligible patients were considered evaluable for response. Age ranged between 36 years and 82 years. Fifty-six of 58 evaluable patients were postmenopausal. An overall remission rate of 48% was achieved with i.m. MPA, 50% with combined (i.m. + p.o.) modalities; only a 19% remission rate was recorded in the p.o. group. Response rate and MPA plasma concentrations were correlated, and a drug level of 80 ng/ml, by means of a GLC method, seems to identify a subset of patients with high probability of response. Only mild toxic effects were recorded.
Department of Medical Oncology, U.L.S.S. 21, Padova, Italy.
A
A
Fornasiero
P
P
Morandi
O
O
Daniele
C
C
Ghiotto
S M
SM
Aversa
A
A
Battaglia
V
V
Fosser
M V
MV
Fiorentino
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001682:Biological Availability; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008875:Middle Aged
D008525:Medroxyprogesterone